The UK National Stem Cell Network has announced that in the new year government – led by the departments of health and business – will undertake a stock-take of regenerative medicine.
Supported by the Research Councils and Technology Strategy Board the work will ensure the UK is able to take account of future developments and that public sector support is appropriate and flexible. It will identify barriers to commercialisation, analyse the current state of the science, and assess the value these products will bring to the NHS and patients.
We should hear more from the Office for Life Sciences in the New Year. It’s not clear whether the new Life Science Business Adviser will be involved in this review but it seems likely it might fall in his remit.